FIELD: chemistry.
SUBSTANCE: present invention relates to immunology. Antibody capable of binding prolactin receptor (PRLR) is proposed. Nucleic acid encoding it, an expression vector and a host cell for producing said antibody are also described. In addition, a pharmaceutical composition comprising said antibody and an antibody-drug conjugate are considered.
EFFECT: antibody of the present invention is useful for detecting PRLR and for inhibiting PRLR activity in a human suffering from a disorder in which PRLR activity is detrimental.
11 cl, 11 dwg, 26 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
ANTIBODIES TARGETING A RECEPTOR BOUND TO G-PROTEINS, AND METHODS FOR USE THEREOF | 2015 |
|
RU2725819C2 |
ANTIBODIES TO GLUCAGON RECEPTOR AND THEREOF APPLICATION | 2009 |
|
RU2562110C2 |
METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
Authors
Dates
2018-08-17—Published
2013-12-23—Filed